- Home
- PGC vs ALLO Comparison
PGC vs ALLO Comparison
Compare PGC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGC | ALLO |
|---|---|---|
| Founded | 1921 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.4M | 707.6M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PGC | ALLO |
|---|---|---|
| Price | $47.39 | $2.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $40.50 | $8.35 |
| AVG Volume (30 Days) | 164.0K | ★ 9.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | 13.51 | ★ 34.09 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $282,995,000.00 | N/A |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | $142,416.42 |
| P/E Ratio | $59.23 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.45 | $0.99 |
| 52 Week High | $49.14 | $4.46 |
Technical Indicators
Market Signals| Indicator | PGC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.00 | 51.37 |
| Support Level | $43.44 | $1.85 |
| Resistance Level | N/A | $2.36 |
| Average True Range (ATR) | 1.39 | 0.13 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 69.13 | 56.41 |
Price Performance
Historical ComparisonAbout PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).